Pseudo-Chediak-Higashi anomaly in acute leukemia. A significant morphologic corollary?
D000328:Adult; D000368:Aged; D001803:Blood Transfusion; D002228:Carbenicillin / Q000627:therapeutic use; D002512:Cephalothin / Q000627:therapeutic use; D002609:Chediak-Higashi Syndrome / Q000097:blood* / Q000150:complications; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006509:Hepatitis B / Q000209:etiology; D006801:Humans; D007709:Klebsiella / Q000302:isolation & purification; D007948:Leukemia, Monocytic, Acute / Q000150:complications*; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000150:complications* / Q000628:therapy; D007968:Leukoencephalopathy, Progressive Multifocal / Q000209:etiology; D008169:Lung Abscess / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology; D014552:Urinary Tract Infections / Q000382:microbiology / Q000628:therapy; D014750:Vincristine / Q000627:therapeutic use
D005839:Gentamicins; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D002228:Carbenicillin; D002512:Cephalothin; D011241:Prednisone